Dihydromyricetin attenuates neuropathic pain via enhancing the transition from M1 to M2 phenotype polarization by potentially elevating ALDH2 activity in vitro and vivo

BACKGROUND: Treatment for neuropathic pain as a refractory disease remains unsatisfactory and represents a significant clinical challenge. A highly effective drug is thus urgently needed for neuropathic pain treatment. Dihydromyricetin (DMY) is a flavonoid with a wide range of biological activities....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Yang, Lingxiao, Li, Longyun, Feng, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576025/
https://www.ncbi.nlm.nih.gov/pubmed/33241000
http://dx.doi.org/10.21037/atm-20-5838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576025/
https://www.ncbi.nlm.nih.gov/pubmed/33241000
http://dx.doi.org/10.21037/atm-20-5838

Ejemplares similares